Support Us


Hyperbaric Oxygen Treatment (HBOT) Study:

Jamesy is one of the first children with Duchenne Muscular Dystrophy to undergo HBOT treatment. Through this study, his marked improvements have led to the first ever hyperbaric pre-clinical trial to be hosted by the University of Minnesota. The launch of the HBOT research is a primary focus of our current fundraising efforts. The findings may provide the vital information needed to prove the clinical efficacy of oxygen therapy, and could lay the groundwork to make this treatment available to all children suffering from Duchenne.

The goal of the HBOT study is to enable these children to walk for as long as possible, until a cure can be found.

Hypoxia as a Modulator of Cardiac Disease in Duchenne Muscular Dystrophy

by Dr. DeWayne Townsend

View Presentation

Duchenne Muscular Dystrophy

and the effects of the Hyperbaric Chamber


Hyperbaric oxygen is a necessity for the mitochondria—the powerhouse of cells. Read more at Health & Wellness Magazine

Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy

Help us find a cure for Duchenne Muscular Dystrophy